Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. - Wikidata - wikimedia - TriplyDB

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q34721817

about

Systemic Sclerosis and Malignancy: A Review of Current Data Current perspectives in bladder cancer management Second malignant neoplasms and cardiovascular disease following radiotherapy.Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer Protective Effect of Thymoquinone against Cyclophosphamide-Induced Hemorrhagic Cystitis through Inhibiting DNA Damage and Upregulation of Nrf2 Expression Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.Molecular mechanisms and pathways in bladder cancer development and progression.Pooling prospective studies to investigate the etiology of second cancers.Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study.Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype Current knowledge and future research directions in treatment-related second primary malignancies.Estimated radiation exposure from medical imaging in hemodialysis patients Treatment of neuro-Behçet's disease: an update.Renal cell carcinoma with proliferative lupus nephritis.De novo malignancy after paediatric renal replacement therapy.Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide Second malignancies among elderly survivors of cancer.Chemotherapy and thyroid cancer risk: a report from the childhood cancer survivor study.A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.Second malignancies in patients with primary central nervous system lymphoma.Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'Bladder cancer: a simple model becomes complex.Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia.Yield of Urinalysis Screening in Pediatric Cancer Survivors.Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma.Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.Urological implications of cyclophosphamide and ifosfamide.Radiation-associated urinary bladder cancer.Chemotherapy-induced bladder cancer.Late effects on the urinary bladder in patients treated for cancer in childhood: a report from the Children's Oncology Group.Radical cystectomy is the treatment of choice for invasive bladder cancer Bladder cancer in cancer patients: population-based estimates from a large Swedish study.Glucocorticoid therapy and risk of bladder cancer Oncologists' and primary care physicians' awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors.Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder.Alternative therapies: what role do they have in the management of lupus?

P2860

Q26740318-0D35406C-502E-4579-83E2-48B711944150 Q26824914-FE41A327-CC4C-463C-91F9-0BAB1F247419 Q26864522-7BBFA0D5-DD09-49AD-A76A-EF7011CF91B0 Q28076041-82D4A772-17A6-4700-8D32-DEFB92BD6F76 Q28385767-0BA755CA-0CF3-4E1D-81F3-1CC0C472C78A Q33346685-A5BE24D1-8E98-4F78-8628-C0CDE3BCA975 Q33715801-ACC3D10B-C0FD-4F52-AF4A-13790DC5FCC4 Q33968710-28E9476D-2A6C-469D-8C46-E643A57447EF Q33992357-CE9589EC-985C-40F7-A5A6-55462BA7375E Q34352780-B01625E6-AF48-4BFE-861B-97E996196854 Q34488720-0298F380-975E-4FE9-851E-E68343691A23 Q34604460-C105E3F9-E81B-494F-92B2-889C5BD50077 Q34695442-5197F9D2-51D0-4E6D-BC7F-2A82A80B39F1 Q34974052-BAA72021-8407-4BA4-9F84-102CEF21928E Q35015758-E1BEE800-31F2-424B-A083-65EE35D1B42F Q35271784-0D7AB7FE-D311-4BFD-ACCE-F7D22395A26E Q35553364-5640478C-3231-4BE8-B452-9220AE2B814E Q35599802-DC24008A-CDD7-47EC-8CA6-44E75E6ECDC6 Q35661353-C06CEA69-410B-41F2-A5A1-A64700F756D4 Q35753383-AF175D13-8B4C-4794-8FE4-EE500EEEC956 Q35788720-5BBED472-B117-4DD6-8DCF-8E8E3601A893 Q35998376-4FE13D3F-5968-4AAF-885F-F52334C3E4EB Q36073447-F10E88CE-08CE-490F-B439-62DA66442FCC Q36108115-E47C08F7-99DC-4F12-A185-5C8AE796A63A Q36265388-5C9610C9-44F8-4D75-9A71-C9BA8385B5C3 Q36528733-3B5E9B91-B05D-487F-8198-B905604F7573 Q36641656-5AF4EF0D-893E-4121-926B-907B26A784A5 Q36711759-D2336A4A-5F5D-4F2E-92EF-6ADAF5A5DB7D Q36911493-AC6894DC-131F-49EC-A086-0678AB4D423C Q37227682-9D6DE76E-52F5-438F-AC72-8885941FDDD6 Q37264407-604C032B-8B7F-4FF3-A33E-9CD8BBA8B7C4 Q37278975-A210B058-F928-4F69-B5F4-A5E19785C16D Q37278978-4E7F0E6F-F343-42EE-908C-2F46BBF3A1ED Q37318045-85816ED9-13D4-4231-8296-31B67289CF6C Q37378993-BBA10C29-7A9A-4DBF-A8F5-FCAB5BE0D13E Q37400498-EB41E7D3-3753-4BDC-9CFD-6DB5E20E13C2 Q37401519-66326811-8E0E-4BEE-9AB7-5B63AC88F649 Q37628663-7BF8AA40-8080-4312-AE75-1F6511878F2B Q37687383-DE0EF96A-F08C-4301-9071-84C83A424E93 Q37800300-4D2AD435-FAA5-46D1-A61F-E1CB19FC238C

P2860

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q34721817

description

1995 nî lūn-bûn

@nan

1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

@ast

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

@en

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

@nl

type

label

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

@ast

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

@en

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

@nl

prefLabel

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

@ast

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

@en

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

@nl

P1433

Q34721817-82CBDBE4-D9DC-4814-8E3F-4251C710F0CE

P1476

Q34721817-894ED0B3-30B5-4C32-BC7E-E19168FBF747

P2093

Q34721817-08F8F6F5-25CD-44F7-9884-0A3744ED16A8

Q34721817-0CE641EB-0395-4F48-8A88-24BCD482F690

Q34721817-1D5C0690-2A5B-4DDE-806D-04B1189A0039

Q34721817-6EEF6673-6B28-4F2C-B27F-CCF6E7451822

Q34721817-8FEEC292-4C40-426F-8C7E-0BDD7CF9EDE2

Q34721817-C9E5C11C-39CD-416B-BA8A-AC6E000BC1AE

Q34721817-CA9C6C3F-ACB9-435E-A00B-AB944A55F0EB

Q34721817-D5349150-C695-432F-8047-59577DA39F22

Q34721817-D8D1C025-0899-4FC6-AE9C-2DD9E4783782

P304

Q34721817-7A1713ED-67D3-47BB-9D9C-A71FBBD9E98A

P31

Q34721817-DC31F2F1-0971-4C4B-8924-164BD17D33FF

P356

Q34721817-754769C9-1990-47FD-AAC7-F71506C42F03

P407

Q34721817-3D0DA2E3-8727-4A0E-977C-BBF2E3B7C4C3

P433

Q34721817-F4992BD8-599A-4407-90CA-8DC360D49D49

P478

Q34721817-5C86AF0D-6096-44DE-99EA-975CF85CF571

P50

Q34721817-1B10BE33-737A-4F68-943A-3ABF878548A1

P577

Q34721817-3EACEA03-797F-491E-9119-B3343DE12526

P698

Q34721817-51E59FA2-73D8-4F7A-868E-B0599C5C2CF6

P356

P1433

Journal of the National Cancer Institute

P1476

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

@en

P2093

Adami J

http://www.w3.org/2001/XMLSchema#string

Banks PM

http://www.w3.org/2001/XMLSchema#string

Curtis RE

http://www.w3.org/2001/XMLSchema#string

Hagenbeek A

http://www.w3.org/2001/XMLSchema#string

Holowaty EJ

http://www.w3.org/2001/XMLSchema#string

Lynch CF

http://www.w3.org/2001/XMLSchema#string

Stovall M

http://www.w3.org/2001/XMLSchema#string

Travis LB

http://www.w3.org/2001/XMLSchema#string

Van Leeuwen FE

http://www.w3.org/2001/XMLSchema#string

P304

524-530

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/87.7.524

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P50

Bengt Glimelius

P577

1995-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7707439

http://www.w3.org/2001/XMLSchema#string